GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptamer Group PLC (LSE:APTA) » Definitions » Construction In Progress

Aptamer Group (LSE:APTA) Construction In Progress : £0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Aptamer Group Construction In Progress?


Aptamer Group Construction In Progress Historical Data

The historical data trend for Aptamer Group's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptamer Group Construction In Progress Chart

Aptamer Group Annual Data
Trend Mar19 Mar20 Jun22 Jun23
Construction In Progress
- - - -

Aptamer Group Semi-Annual Data
Mar19 Mar20 Dec21 Jun22 Dec22 Jun23 Dec23
Construction In Progress Get a 7-Day Free Trial - - - - -

Aptamer Group Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Aptamer Group (LSE:APTA) Business Description

Traded in Other Exchanges
N/A
Address
Innovation Way, Windmill House, York, GBR, YO10 5BR
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics.

Aptamer Group (LSE:APTA) Headlines

No Headlines